Smoking, inflammation, vascular disease: Quit now.

Javed Iqbal*

Department of Pulmonology, Qatar University, Qatar

Introduction

This meta-analysis explores how smoking cessation impacts lung inflammation in individuals with chronic obstructive pulmonary disease (COPD). It consolidates evidence suggesting that quitting smoking significantly reduces various inflammatory markers, highlighting a crucial mechanism by which cessation improves respiratory health outcomes. The findings underscore the importance of smoking cessation as a primary intervention for managing inflammation in smoking-related lung diseases [1]

Here's the thing, this review delves into how nicotine and broader tobacco smoke exposure contribute to the initiation and worsening of pulmonary hypertension. It unpacks the specific pathological mechanisms involved, giving us a clearer picture of the direct link between smoking and changes in the pulmonary vasculature that lead to elevated pressures. Understanding these mechanisms is key to preventing and treating smoking-induced PH [2]

This review sheds light on the complex relationship between chronic airway inflammation, especially in conditions like COPD, and the emergence and progression of pulmonary hypertension. What this really means is that ongoing inflammation in the airways contributes significantly to the vascular changes seen in PH. The article also touches on current therapeutic strategies aimed at mitigating this interconnected pathology [3]

Let's break it down: this study reveals a direct cellular mechanism. It shows how components from cigarette smoke promote the proliferation and migration of smooth muscle cells in the pulmonary arteries. This process, driven by the HIF-1α/PDGF-BB signaling pathway, is a fundamental step in the vascular remodeling that defines pulmonary hypertension, illustrating smoking's direct impact at the cellular level [4]

This systematic review and meta-analysis offers compelling evidence. It demonstrates that when patients with COPD quit smoking, it leads to significant improvements in various inflammatory markers. This suggests that smoking cessation isn't just about stopping lung damage, but actively reversing or reducing the inflammatory state, which is vital for improving overall respiratory health and mitigating disease progression [5]

This updated article clarifies how pulmonary hypertension develops in the context of emphysema, a condition strongly linked to smoking and chronic inflammation. It provides an in-depth look at the pathological changes, particularly in vascular remodeling, showing how the destructive processes of emphysema directly contribute to elevated pulmonary pressures. This offers a clear view of the disease's progression [6]

Here's an important insight: this review examines the role of NADPH oxidase and the resulting oxidative stress in pulmonary vascular remodeling, a process central to pulmonary hypertension. Since smoking is a major driver of oxidative stress, this article connects the dots between smoking, inflammation, and PH by highlighting a specific molecular pathway. It also points towards potential therapeutic targets that could interrupt this destructive cycle [7]

This article delves into the current understanding of smoking cessation's clinical benefits for patients with COPD. It stresses how quitting smoking can slow disease progression, and crucially, how it might mitigate severe complications like pulmonary hypertension. Given that ongoing inflammation exacerbated by smoking worsens both conditions, these insights are essential for patient management and improving long-term outcomes [8]

This article clarifies the strong link between systemic inflammation and microvascular dysfunction frequently observed in smokers. It's important because it shows how these smoking-induced factors contribute not just to general vascular problems, but specifically to the development and progression of pulmonary hypertension. Understanding this connection is vital for appreciating the broad impact of smoking on vascular health [9]

This research zeroes in on the crucial role of the NLRP3 inflammasome, a major inflammatory pathway, in the development of pulmonary hypertension caused by cigarette smoke. What we learn here is that targeting this specific inflammatory mechanism could offer novel therapeutic avenues. It provides a detailed look into the molecular underpinnings of how smoking drives PH through inflammatory processes [10]

***Correspondence to:** Javed Iqbal, Department of Pulmonology, Qatar University, Qatar. E-mail: javed.iqbal@qataruniv.edu.qa

Received: 01-Jul-2025, Manuscript No. AAJPCR-25-215; **Editor assigned:** 03-Jul-2025, Pre QC No. AAJPCR-25-215 *(PQ)*; **Reviewed:** 23-Jul-2025, QC No. AAJPCR-25-215; **Revised:** 01-Aug-2025, Manuscript No. AAJPCR-25-215 *(R)*; **Published:** 12-Aug-2025, DOI: 10.35841/aajpcr-8.4.215

Citation: Iqbal J. Smoking, inflammation, vascular disease: Quit now. J Pulmonol Clin Res. 2025;08(04):215.

Conclusion

Smoking has a profound impact on both respiratory and vascular health, with significant implications for conditions like Chronic Obstructive Pulmonary Disease (COPD) and pulmonary hypertension (PH). Research consistently shows that quitting smoking profoundly reduces lung inflammation in individuals with COPD, actively improving respiratory health outcomes by diminishing various inflammatory markers. This highlights smoking cessation as a primary intervention for managing inflammation in smoking-related lung diseases. Furthermore, the act of quitting smoking demonstrably slows disease progression in COPD and can mitigate severe complications, notably pulmonary hypertension, which is crucial for enhancing long-term patient outcomes.

Beyond general inflammation, tobacco smoke exposure and nicotine directly contribute to the initiation and worsening of PH by inducing specific pathological mechanisms and structural changes within the pulmonary vasculature. Chronic airway inflammation, particularly prevalent in conditions like COPD, also plays a significant role in driving the vascular changes that lead to PH. On a cellular level, components from cigarette smoke actively promote the proliferation and migration of smooth muscle cells in pulmonary arteries through specific signaling pathways, a fundamental step in vascular remodeling characteristic of PH. Conditions like emphysema, which are strongly linked to smoking and chronic inflammation, further exemplify how destructive processes directly contribute to elevated pulmonary pressures.

Molecular insights reveal that smoking-induced oxidative stress, often mediated by NADPH oxidase, is a key player in pulmonary vascular remodeling, presenting potential therapeutic targets. Systemic inflammation and microvascular dysfunction are frequently observed in smokers, linking these factors directly to the development and progression of PH. A major inflammatory pathway, the NLRP3 inflammasome, is crucial in cigarette smoke-induced PH, suggesting that targeting this mechanism could offer novel therapeutic approaches. These findings collectively underscore the complex interplay between smoking, inflammation, and vascular changes, while emphasizing the indispensable role of smoking cessation in prevention and management.

References

1. Zhou Y, Fan X, Lv Z. Cigarette smoking cessation and lung inflammation in chronic obstructive pulmonary disease: a meta-analysis. *Respir Res.* 2020;21:24.
2. Hemnes AR, Trammell AW, *Champion HC. Nicotine and tobacco smoke exposure and development of pulmonary hypertension. Pulm Circ.* 2020;10:2045894020914614.
3. Chaouat A, Chaaben H, de Blic R. Pulmonary hypertension in chronic obstructive pulmonary disease: *Current understanding and therapeutic strategies. Rev Mal Respir.* 2022;39:120-137.
4. Zhou C, Zhang Y, Zhu H. Cigarette smoke extract induces pulmonary artery smooth muscle cell proliferation and migration via activation of HIF-1α/PDGF-BB signaling pathway. *Environ Toxicol.* 2020;35:72-81.
5. Ma P, Zhang Y, Wang S. Smoking Cessation and Inflammatory Markers in Patients With COPD: A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2021;12:629391.
6. Al-Hakami K, Hussain SA, Khan A. Pathobiology of pulmonary hypertension in emphysema: *An update. J Saudi Heart Assoc.* 2022;34:272-282.
7. Das R, Dhingra R, Arora S. NADPH oxidase in pulmonary vascular remodeling: therapeutic potential in pulmonary hypertension. *Pharmacol Res.* 2020;161:105213.
8. Yang S, Fu Z, Luo Y. Smoking Cessation in Patients with COPD: *Latest Evidence and Therapeutic Implications. J Clin Med.* 2023;12:2960.
9. Taraseviciene-Stewart L, Tamosiunas A, Ryselis S. Systemic inflammation and microvascular dysfunction in smokers: linking risk factors to vascular disease. *J Clin Med.* 2023;12:1451.
10. Liu S, Fan S, Wang R. Role of NLRP3 inflammasome in cigarette smoke-induced pulmonary hypertension. *Int Immunopharmacol.* 2020;78:106001.

Citation: *Iqbal J. Smoking, inflammation, vascular disease: Quit now. J Pulmonol Clin Res. 2025;08(04):215.*